Loading company
ONCBeone Medicines Ltd.$47.6BA+Built from uniQure N.V.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes uniQure is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$23.84-3.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From uniQure's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$5.2M
+40% y/y
-11% q/q
Guided
—
No guide given
Actual
-$0.88
Guided
—
No guide given
Actual
-$53M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade F-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 39 quarters of uniQure N.V.’s grade history. The other 37 go back to March 2017.
